ATRC
14.2.2024 16:13:28 CET | Business Wire | Press release
Abu Dhabi’s Advanced Technology Research Council (ATRC) signed a Memorandum of Understanding (MoU) with the Ministry of Information and Telecommunications of the Republic of Serbia, and the Institute for Artificial Intelligence Research and Development of Serbia. This landmark collaboration aims to leverage the technical expertise of ATRC and its subsidiaries for integration of Artificial Intelligence (AI) into Serbia’s technological infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240214719869/en/
His Excellency Shahab Issa Abu Shahab, Director General of ATRC, Mihailo Jovanović, Minister of Information and Telecommunications of the Republic of Serbia and Dubravko Culibrk, Director of the Institute for AI Research and Development of Serbia signed a Memorandum of Understanding on the sidelines of the World Government Summit 2024. (Photo: AETOSWire)
Under the terms of the MoU, Serbia will support the adoption of the ATRC’s Falcon large language models (LLM) and explore avenues of collaboration with ATRC around Falcon-powered solutions. Furthermore, both entities will work together to encourage organizations from Serbia to join the Falcon Foundation and contribute to the success of open-source Falcon models.
The MoU was signed by His Excellency Shahab Issa Abu Shahab, Director General of ATRC, Mihailo Jovanovic, Minister of Information and Telecommunications of the Republic of Serbia, and Dubravko Culibrk, Director of the Institute for AI Research and Development of Serbia, on the sidelines of the World Governments Summit 2024.
Expressing optimism about the alliance, His Excellency Shahab Issa Abu Shahab, Director General of ATRC said: “AI is a powerful catalyst for innovation and progress. The collaboration between ATRC, the Serbian Ministry of IT, and its Institute of AI Research and Development, marks a critical milestone as we witness an increasing global interest in adopting Falcon. Our shared commitment to the Falcon open-source models ensures a dynamic and inclusive approach to advancing AI capabilities worldwide.”
For his part, Mihailo Jovanović, Minister of Information and Telecommunications of the Republic of Serbia said, “We are taking a step further and thanks to the expertise of the Advanced Technology Research Council (ATRC), we are starting to use and apply Falcon open source models for the development of AI in Serbia. This step forward will help us in further implementation of modernization projects within the Serbia 2027 Programme and strengthen the position of Serbia as a technological and digital leader in the region of Southeast Europe.”
Dubravko Culibrk, Director of the Institute for AI Research and Development of Serbia, also remarked: “We are thrilled to embark on this transformative journey with ATRC. By integrating Falcon open-source models across the board, we aim to drive breakthroughs in AI research and development. Partnerships with governments worldwide are crucial for creating an environment where innovation flourishes, ensuring that AI becomes a driving force for positive change.”
The Falcon LLMs are a family of powerful, open-source large language models developed by the Technology Innovation Institute, ATRC’s applied research arm.
The partnership marks a significant stride in exporting Falcon’s capability at a country level beyond the Middle East, laying the groundwork for global collaborative initiatives that will shape the future of technological innovation.
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240214719869/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom